Merck KGaA - Oct 21, 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
/s/ Christian Uhrich, Authorized signatory of Merck KGaA, Darnstadt, Germany
Stock symbol
XLO
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:50 PM
Next filing
Oct 26, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Series B Preferred Stock Oct 21, 2021 Common Stock 416K See footnote F1, F2
holding XLO Series C Preferred Stock Oct 21, 2021 Common Stock 265K See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F2 The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
F3 The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.